Related Experiment Video
Updated: Jun 13, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran: ready for prime time?
Ganesan Karthikeyan1, John W Eikelboom, Jack Hirsh
1Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India. karthik2010@gmail.com
Polskie Archiwum Medycyny Wewnetrznej
|April 29, 2010
Summary
New studies show dabigatran, a direct thrombin inhibitor, is effective in preventing venous thromboembolism and atrial fibrillation outcomes compared to warfarin. Dabigatran offers a convenient, monitor-free alternative for long-term anticoagulation therapy.
Area of Science:
- Pharmacology and Clinical Medicine
- Cardiovascular Thrombosis and Anticoagulation
Background:
- Selective inhibitors of factor Xa and thrombin are effective in preventing venous thromboembolism in high-risk surgical patients.
- These agents offer predictable dose-response, potentially improving anticoagulation quality and patient convenience by eliminating routine laboratory monitoring.
Purpose of the Study:
- To critically review two large trials comparing dabigatran (a direct thrombin inhibitor) with warfarin.
- To discuss the feasibility of replacing warfarin with dabigatran for indications such as atrial fibrillation and venous thromboembolism.
Main Methods:
- Analysis of results from two major clinical trials involving dabigatran and warfarin.
- Critical review of trial data focusing on patient-important clinical outcomes.
Main Results:
- The trials provide convincing evidence of dabigatran's efficacy in preventing key clinical outcomes.
- Dabigatran demonstrated comparable or superior efficacy to warfarin in the studied patient populations.
Conclusions:
- Dabigatran is a highly effective anticoagulant, offering a viable alternative to warfarin.
- The convenience and efficacy of dabigatran suggest its potential to replace warfarin for specific indications, improving patient care.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...